Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation

Transplant Immunology

Volumn 32, Issue 1, 2015, Pages 18-22

  Valke, Lars L F G ^a   van Cranenbroek, Bram ^a   Hilbrands, Luuk B ^a   Joosten, Irma ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute rejection; Renal transplantation; Rituximab; SCD30

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CD30 ANTIGEN; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; TACROLIMUS; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE PERIOD; PREDICTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SERUM; SURGICAL PATIENT; TREATMENT DURATION; TREATMENT RESPONSE; ACUTE DISEASE; BLOOD; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; TIME;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD30; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS;

EID: 84920401248     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2014.10.006     Document Type: Article

References (29)

1. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 2005, 56:71-85.
2. Taylor A.L., Watson C.J., Bradley J.A. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005, 56:23-46.
3. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351:2715-2729.
4. Susal C., Dohler B., Sadeghi M., Salmela K.T., Weimer R., Zeier M., et al. Posttransplant sCD30 as a Predictor of Kidney Graft Outcome. Transplantation 2011, 91:1364-1369.
5. Pelzl S., Opelz G., Daniel V., Wiesel M., Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75:421-423.
6. Susal C., Pelzl S., Simon T., Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 2004, 36:29-34.
7. Dong W., Shunliang Y., Weizhen W., Qinghua W., Zhangxin Z., Jianming T., et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006, 16:41-45.
8. Delgado J.C., Pavlov I.Y., Shihab F.S. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study. Transpl Immunol 2009, 22:1-4.
9. Chen Y., Tai Q., Hong S., Kong Y., Shang Y., Liang W., et al. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis. Transplantation 2012, 94:911-918.
10. Hirt-Minkowski P., Roth M., Honger G., Amico P., Hopfer H., Schaub S. Soluble CD30 correlates with clinical but not subclinical renal allograft rejection. Transpl Int 2013, 26:75-83.
11. Sengul S., Keven K., Gormez U., Kutlay S., Erturk S., Erbay B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006, 81:1216-1219.
12. Cervelli C., Fontecchio G., Scimitarra M., Azzarone R., Famulari A., Pisani F., et al. Evaluation of serum sCD30 in renal transplantation patients with and without acute rejection. Transplant Proc 2009, 41:1159-1161.
13. Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68:421-427.
14. Pellegrini P., Berghella A.M., Contasta I., Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003, 12:49-61.
15. Martinez O.M., Villanueva J., Abtahi S., Beatty P.R., Esquivel C.O., Krams S.M. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998, 65:1240-1247.
16. Kreijveld E., Koenen H.J., van Cranenbroek B., van Rijssen E., Joosten I., Hilbrands L.B. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One 2008, 3:e2711.
17. Susal C., Pelzl S., Dohler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13:1650-1656.
18. Pelzl S., Opelz G., Wiesel M., Schnulle P., Schonemann C., Dohler B., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73:3-6.
19. Wang D., Wu W.Z., Chen J.H., Yang S.L., Wang Q.H., Zeng Z.X., et al. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients. Transpl Immunol 2010, 22:115-120.
20. Kovac J., Arnol M., Vidan J.B., Bren A.F., Kandus A. Pretransplant soluble CD30 serum concentration does not affect kidney graft outcomes 3years after transplantation. Transplant Proc 2010, 42:4043-4046.
21. Heinemann F.M., Rebmann V., Witzke O., Philipp T., Broelsch C.E., Grosse-Wilde H. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 2007, 83:706-711.
22. Altermann W., Schlaf G., Rothhoff A., Seliger B. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?. Nephrol Dial Transplant 2007, 22:2795-2799.
23. Weimer R., Susal C., Yildiz S., Staak A., Pelzl S., Renner F., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006, 6:1865-1874.
24. Barraclough K.A., Staatz C.E., Johnson D.W., Gillis D., Lee K.J., McWhinney B.C., et al. A differential impact of mycophenolic acid, prednisolone, and tacrolimus exposure on sCD30 levels in adult kidney transplant recipients. Ther Drug Monit 2013, 35:240-245.
25. Fabrega E., Unzueta M.G., Cobo M., Casafont F., Amado J.A., Romero F.P. Value of soluble CD30 in liver transplantation. Transplant Proc 2007, 39:2295-2296.
26. Matinlauri I., Hockerstedt K., Isoniemi H. High serum soluble CD30 does not predict acute rejection in liver transplant patients. Transplant Proc 2006, 38:3601-3604.
27. Golocheikine A.S., Saini D., Ramachandran S., Trulock E.P., Patterson A., Mohanakumar T. Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation. Transpl Immunol 2008, 18:260-263.
28. Kwakkel-van Erp J.M., Otten H.G., Paantjens A.W., van Kessel D.A., van Ginkel W.G., van den Bosch J.M., et al. Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen. J Heart Lung Transplant 2008, 27:1172-1175.
29. Ypsilantis E., Key T., Bradley J.A., Morgan C.H., Tsui S., Parameshwar J., et al. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome. J Heart Lung Transplant 2009, 28:1206-1210.